Published in J Acquir Immune Defic Syndr on January 01, 1990
Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J Virol (1996) 2.83
Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J Virol (1995) 2.48
Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J Virol (1995) 1.80
Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee. J Clin Microbiol (1993) 1.78
Sensitive microculture method for isolation of human immunodeficiency virus type 1 from blood leukocytes. J Clin Microbiol (1992) 1.29
Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel) (2010) 1.22
Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa. J Virol (1996) 1.14
Accumulation of activated CD4+ lymphocytes in the lung of individuals infected with HIV accompanied by increased virus production in patients with secondary infections. Clin Exp Immunol (1995) 0.79
Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group. J Clin Microbiol (1996) 0.77
Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science (1986) 7.81
Human immunodeficiency virus infections among civilian applicants for United States military service, October 1985 to March 1986. Demographic factors associated with seropositivity. N Engl J Med (1987) 2.81
Plasmodium falciparum incidence relative to entomologic inoculation rates at a site proposed for testing malaria vaccines in western Kenya. Am J Trop Med Hyg (1994) 2.73
HTLV-III in symptom-free seronegative persons. Lancet (1984) 2.71
Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med (1993) 2.61
Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med (1987) 2.59
Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses (1992) 2.52
The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med (1986) 2.44
Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis (1994) 2.42
Type-restricted neutralization of molecular clones of human immunodeficiency virus. Science (1988) 2.31
Measurement of the false positive rate in a screening program for human immunodeficiency virus infections. N Engl J Med (1988) 2.22
Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol (1985) 2.20
Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science (1987) 2.11
False-positive Western blot tests for antibodies to HTLV-III. JAMA (1986) 2.07
Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med (1986) 2.03
Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis (1994) 2.02
Characterization of malaria transmission by Anopheles (Diptera: Culicidae) in western Kenya in preparation for malaria vaccine trials. J Med Entomol (1990) 2.02
Brief communication: C-type particles in normal human placentas. J Natl Cancer Inst (1973) 1.80
Frequent transmission of HTLV-III among spouses of patients with AIDS-related complex and AIDS. JAMA (1985) 1.76
Characterization of HIV isolates arising after prolonged zidovudine therapy. J Acquir Immune Defic Syndr (1992) 1.72
Specific inhibition of lymphocyte-proliferation responses by adherent suppressor cells in diffuse cutaneous leishmaniasis. N Engl J Med (1982) 1.68
Human immunodeficiency virus infections in teenagers. Seroprevalence among applicants for US military service. The Walter Reed Retrovirus Research Group. JAMA (1990) 1.67
Heterosexually acquired HTLV-III/LAV disease (AIDS-related complex and AIDS). Epidemiologic evidence for female-to-male transmission. JAMA (1985) 1.65
Primary isolation and serial passage of hepatitis A virus strains in primate cell cultures. J Clin Microbiol (1984) 1.61
Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA (1987) 1.59
Prevalence and incidence of HTLV-III infection in a prison. JAMA (1986) 1.48
Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns. J Virol (1991) 1.48
Look-back investigation after human immunodeficiency virus seroconversion in a pediatric dentist. J Infect Dis (1994) 1.46
Prompt confirmation of Rocky Mountain spotted fever: identification of rickettsiae in skin tissues. J Infect Dis (1976) 1.46
Naturally occurring genotypes of the human immunodeficiency virus type 1 long terminal repeat display a wide range of basal and Tat-induced transcriptional activities. J Virol (1994) 1.40
Early mutants of polyoma virus (dl8 and dl23) with altered transformation properties: is polyoma virus middle T antigen a transforming gene product? Cold Spring Harb Symp Quant Biol (1980) 1.39
The threat of infectious diseases in Somalia. N Engl J Med (1993) 1.38
Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci U S A (2003) 1.38
Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol (1995) 1.37
Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet (1985) 1.35
Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol (1994) 1.35
Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res (2001) 1.34
Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med (1986) 1.34
Variations in Western blot banding patterns of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. J Clin Microbiol (1987) 1.33
Induction of interleukin-6 during human immunodeficiency virus infection. Blood (1990) 1.32
Diagnosis of human immunodeficiency virus infection by immunoassay using a molecularly cloned and expressed virus envelope polypeptide. Comparison to Western blot on 2707 consecutive serum samples. Ann Intern Med (1987) 1.32
Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg (1985) 1.31
Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J Virol (1995) 1.30
Negative-strand RNA transcripts are produced in human immunodeficiency virus type 1-infected cells and patients by a novel promoter downregulated by Tat. J Virol (1994) 1.29
Differences in the interaction of HIV-1 and HIV-2 with CD4. J Acquir Immune Defic Syndr (1990) 1.24
Human lymphocyte proliferative response to a sporozoite T cell epitope correlates with resistance to falciparum malaria. J Immunol (1989) 1.24
Inhibition of lymphocyte transformation by disrupted murine oncornavirus. Cancer Res (1977) 1.24
Hormone-activated expression of the C-type RNA tumour virus genome. Nat New Biol (1971) 1.21
Activation of macrophages to kill rickettsiae and Leishmania: dissociation of intracellular microbicidal activities and extracellular destruction of neoplastic and helminth targets. Contemp Top Immunobiol (1984) 1.20
ELISA method for detecting Plasmodium falciparum circumsporozoite antibody. Bull World Health Organ (1989) 1.20
The presence of unique DNA sequences after viral induction of leukemia in mice. (RNA tumor virus-nucleic acid hybridization-insertion of viral DNA). Proc Natl Acad Sci U S A (1974) 1.19
Impact of transmission intensity and age on Plasmodium falciparum density and associated fever: implications for malaria vaccine trial design. J Infect Dis (1995) 1.19
Binding characteristics of Rauscher leukemia virus envelope glycoprotein gp71 to murine lymphoid cells. J Virol (1977) 1.18
Genetic analysis of HIV-1 isolates from Zambia and an expanded phylogenetic tree for HIV-1. J Acquir Immune Defic Syndr (1992) 1.16
Dose- and time-dependent relations between infective Anopheles inoculation and outcomes of Plasmodium falciparum parasitemia among children in western Kenya. Am J Epidemiol (1997) 1.14
The threat of infectious disease in Americans returning from Operation Desert Storm. N Engl J Med (1991) 1.14
Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA (1985) 1.13
Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg (1987) 1.13
ShcA and Grb2 mediate polyoma middle T antigen-induced endothelial transformation and Gab1 tyrosine phosphorylation. EMBO J (2001) 1.12
Situational analysis of varying models of adherence support and loss to follow up rates; findings from 27 treatment facilities in eight resource limited countries. Trop Med Int Health (2010) 1.12
Predicting outcome in malaria: correlation between rate of exposure to infected mosquitoes and level of Plasmodium falciparum parasitemia. Am J Trop Med Hyg (1994) 1.10
Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. Am J Trop Med Hyg (1982) 1.09
Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol (1986) 1.09
Malaria in asplenic mice: effects of splenectomy, congenital asplenia, and splenic reconstitution on the course of infection. Am J Trop Med Hyg (1980) 1.08
Decentralization of CD4 testing in resource-limited settings: 7 years of experience in six African countries. Cytometry A (2011) 1.08
Frequent isolation of HIV-1 from the blood of patients receiving zidovudine (AZT) therapy. N Engl J Med (1989) 1.08
HIV-1 proviral genotypes from the peripheral blood mononuclear cells of an infected patient are differentially represented in expressed sequences. J Acquir Immune Defic Syndr (1993) 1.07
Real-time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gp160, of HIV-1. J Immunol Methods (1992) 1.07
Baboon virus isolate M-7 with properties similar to feline virus RD-114. J Virol (1974) 1.06
Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J Infect Dis (1998) 1.04
Laboratory-acquired Rocky Mountain spotted fever. The hazard of aerosol transmission. N Engl J Med (1977) 1.04
Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG. J Infect Dis (1997) 1.03
Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis (1998) 1.00
Trends of HIV seroconversion among young adults in the US Army, 1985 to 1989. US Army Retrovirus Research Group. JAMA (1991) 0.99
Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis (2000) 0.99
Studies of the blastogenic response of murine lymphocyte. 3. Specific viral transformation. Proc Soc Exp Biol Med (1972) 0.98
Removal of contaminating DNA from PCR reagents by ultrafiltration. Biotechniques (1994) 0.98
Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84). J Infect Dis (1979) 0.98
Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United States. J Clin Microbiol (1992) 0.98
Plasmodium falciparum gametocytemia in Kenyan children: associations among age, intensity of exposure to transmission, and prevalence and density of subsequent gametocytemia. Am J Trop Med Hyg (1997) 0.94
Biologic factors and response to radiotherapy in carcinoma of the cervix. Int J Gynecol Cancer (2001) 0.93
Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk? Perspect Biol Med (1992) 0.93
Direct isolation of xenotropic retraviruses from the NIH swiss mouse uterus. Virology (1977) 0.93
Initial clinical evaluation of a new Rocky Mountain spotted fever vaccine of tissue culture origin. J Infect Dis (1978) 0.91
Tracking the spread of the HIV infection epidemic among young adults in the United States: results of the first four years of screening among civilian applicants for U.S. military service. J Acquir Immune Defic Syndr (1990) 0.91
Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. J Infect Dis (2000) 0.91
Predictors of HIV-1 disease progression in early- and late-stage patients: the U.S. Army Natural History Cohort. Military Medical Consortium for Applied Retrovirology. J Acquir Immune Defic Syndr (1992) 0.91
A comparative study on the presence of C-type viral particles in placentas from primates and other animals. Bibl Haematol (1975) 0.91
Isolation of Leishmania donovani from Phlebotomus martini in Baringo district, Kenya. Trans R Soc Trop Med Hyg (1988) 0.91
Evaluation of promastigote and amastigote antigens in the indirect fluorescent antibody test for American cutaneous leishmaniasis. Am J Trop Med Hyg (1983) 0.91
Patterns of antibody recognition of selected conserved amino acid sequences from the HIV envelope in sera from different stages of HIV infection. AIDS Res Hum Retroviruses (1989) 0.91
Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.90
Macrophage activation to kill Leishmania tropica: kinetics of macrophage response to lymphokines that induce antimicrobial activities against amastigotes. J Immunol (1984) 0.90
Post kala-azar dermal leishmaniasis: the Kenyan experience. East Afr Med J (1991) 0.90